Marta López1, Francesc Figueras1, Oriol Coll1, Anna Goncé1, Sandra Hernández1, Montse Loncá2, Jordi Vila3, Eduard Gratacós1, Montse Palacio1. 1. Department of Maternal-Fetal Medicine, BCNatal - Barcelona Center of Maternal-Fetal and Neonatal Medicine (Hospital Clínic and Hospital Sant Joan de Déu), IDIBAPS, Centre for Biomedical Research on Rare Diseases (CIBER-ER). 2. Infectious Diseases Department, Hospital Clinic, IDIBAPS. 3. Department of Microbiology, Hospital Clinic, CRESIB, University of Barcelona, Spain.
Abstract
BACKGROUND: This study was performed to assess the role of lipopolysaccharide modulators as a marker of microbial translocation among human immunodeficiency virus (HIV)-infected women during pregnancy and to evaluate their association with preterm delivery. METHODS: The study had a prospective cohort design and was performed at the Hospital Clínic in Barcelona, Spain. Thirty-six pregnant women with and 36 without HIV infection, matched on the basis of age and parity, were included. Maternal blood samples were obtained during the first trimester, during the third trimester, and at delivery. Levels of soluble CD14 (sCD14), human lipopolysaccharide-binding protein (LBP), immunoglobulin M endotoxin core antibodies to lipopolysaccharide (EndoCAb), and interleukin 6 (IL-6) were determined. Fetal cord blood levels of sCD14, LBP, and IL-6 were determined. Results were compared between groups. RESULTS: First trimester sCD14 and LBP levels and third trimester sCD14 levels were significantly higher in the HIV-infected group. HIV-infected women with preterm births and spontaneous preterm births had significantly increased levels of sCD14 throughout pregnancy and significantly increased levels of LBP during the first trimester, compared with HIV-infected women with delivery at term or with HIV-negative women. On multivariate analysis, an independent association was observed between first trimester sCD14 levels and preterm delivery among HIV-infected women. CONCLUSIONS: This is the first study to assess inflammatory markers related to microbial translocation during pregnancy among HIV-infected women. Higher levels of sCD14 and LBP were observed in HIV-infected pregnant women and were associated with preterm delivery.
BACKGROUND: This study was performed to assess the role of lipopolysaccharide modulators as a marker of microbial translocation among humanimmunodeficiency virus (HIV)-infectedwomen during pregnancy and to evaluate their association with preterm delivery. METHODS: The study had a prospective cohort design and was performed at the Hospital Clínic in Barcelona, Spain. Thirty-six pregnant women with and 36 without HIV infection, matched on the basis of age and parity, were included. Maternal blood samples were obtained during the first trimester, during the third trimester, and at delivery. Levels of soluble CD14 (sCD14), humanlipopolysaccharide-binding protein (LBP), immunoglobulin M endotoxin core antibodies to lipopolysaccharide (EndoCAb), and interleukin 6 (IL-6) were determined. Fetal cord blood levels of sCD14, LBP, and IL-6 were determined. Results were compared between groups. RESULTS: First trimester sCD14 and LBP levels and third trimester sCD14 levels were significantly higher in the HIV-infected group. HIV-infectedwomen with preterm births and spontaneous preterm births had significantly increased levels of sCD14 throughout pregnancy and significantly increased levels of LBP during the first trimester, compared with HIV-infectedwomen with delivery at term or with HIV-negative women. On multivariate analysis, an independent association was observed between first trimester sCD14 levels and preterm delivery among HIV-infectedwomen. CONCLUSIONS: This is the first study to assess inflammatory markers related to microbial translocation during pregnancy among HIV-infectedwomen. Higher levels of sCD14 and LBP were observed in HIV-infected pregnant women and were associated with preterm delivery.
Authors: Kartik K Venkatesh; Andrew Edmonds; Daniel Westreich; Jodie Dionne-Odom; Deborah Jones Weiss; Anandi N Sheth; Helen Cejtin; Dominika Seidman; Seble Kassaye; Howard Minkoff; Jessica Atrio; Lisa Rahangdale; Adaora A Adimora Journal: HIV Med Date: 2021-09-12 Impact factor: 3.094
Authors: Wenwen Jiang; Keshet Ronen; Lusi Osborn; Alison L Drake; Jennifer A Unger; Daniel Matemo; Daniel A Enquobahrie; John Kinuthia; Grace John-Stewart Journal: AIDS Date: 2022-03-04 Impact factor: 4.632
Authors: Charlotte-Eve S Short; Richard G Brown; Rachael Quinlan; Yun S Lee; Ann Smith; Julian R Marchesi; Robin Shattock; Phillip R Bennett; Graham P Taylor; David A MacIntyre Journal: Front Cell Infect Microbiol Date: 2021-02-11 Impact factor: 5.293
Authors: Ethan K Gough; Thaddeus J Edens; Hyun Min Geum; Iman Baharmand; Sandeep K Gill; Ruairi C Robertson; Kuda Mutasa; Robert Ntozini; Laura E Smith; Bernard Chasekwa; Florence D Majo; Naume V Tavengwa; Batsirai Mutasa; Freddy Francis; Lynnea Carr; Joice Tome; Rebecca J Stoltzfus; Lawrence H Moulton; Andrew J Prendergast; Jean H Humphrey; Amee R Manges; Shine Trial Team Journal: EBioMedicine Date: 2021-06-15 Impact factor: 8.143
Authors: Katelyn J Rittenhouse; Humphrey Mwape; Julie A E Nelson; John Mwale; Gabriel Chipili; Joan T Price; Michael Hudgens; Elizabeth M Stringer; Kristina De Paris; Bellington Vwalika; Jeffrey S A Stringer Journal: AIDS Date: 2021-03-15 Impact factor: 4.632